摘要：目的研制离体肾脏灌流装置。方法自行设计、制造一种离体肾脏灌流装置,并进行6例新西兰白兔离体肾脏常温下灌流实验,以评估此灌流装置的工作性能。结果灌流装置能与尿量偶联自动补充灌流液,机器能持续工作,性能稳定。最长灌流保存时间达80.65h。灌流24、48h,肾脏静脉流出液乳酸脱氢酶(LDH)活性、钾钠离子浓度和尿N-乙酰βD-氨基葡萄糖苷酶(NAG)活性无显著变化,肾组织形态学基本正常,当灌流65h,肾静脉流出液LDH活性和钾离子浓度显著增高,钠离子浓度显著降低,尿NAG活性显著增高,肾小管上皮细胞变性肿胀。结论该肾脏体外灌流装置操作简单,使用方便,能满足医学科研的要求。

摘要：目的 :筛选出能与HBV DNAC启动子形成三链结构的高亲和力寡核苷酸。方法 :以体外合成的3 2 P标记的HBV DNAC启动子区序列 ( 173 4～ 175 4)为靶序列 ,合成 5种有可能与该靶序列形成三链结构的寡核苷酸链 (TFO) ,同时设计对照靶序列和对照TFO ,用凝胶滞留试验、酶足迹试验等方法对比分析这些TFO与靶序列是否形成三链结构及其结合的亲和性、特异性。结果 :在 3 7°C、pH7 4条件下 ,CT TFO和GT TFOp与3 2 P 靶序列DNA结合的亲和力十分微弱 ,其Kd均 >10 -6mol/L ;GT TFOap和AG TFOs与靶序列DNA结合的亲和力较高 ,Kd分别为 5× 10 -7mol/L和 2 5× 10 -8mol/L ;AG TFO1与靶序列结合的亲和力最高 ,Kd为 3× 10 -9mol/L ,而且两者的结合具有序列特异性。结论 :含AG或GT的TFO可与HBVC启动子区类同聚嘌呤链逆平行方向结合成三链DNA ,其中AG TFO1与靶序列结合的亲和力最高 ,反应完全 ,可使靶双链DNA均转变成三链DNA ,经一定修饰后 ,可试用于HBV基因转录抑制实验。

摘要：以往用牛血清蛋白(BSA)诱导的肾小球肾炎模型有兔急性血清病和大鼠慢性肾小球肾炎两种。本文报道在此基础上改进的大鼠急性增殖型肾小球肾炎模型及其病理改变。材料与方法一、模型制作与实验设计雌性Wistar大鼠80只,体重200～240g,随机分成模型组和对照组,每组40只,置代谢笼中喂养。于实验前12天将BSA按150mg/***给模型组大鼠腹腔注射1次预免疫,实验第1天再按300mg/***腹腔注射1次。对照组大鼠同时注射等容积的生理盐水代替。于实验第1天(BSA注射前),第7,13,20天4个时相点每组各取8只大鼠作尿蛋白定量、血浆肌酐、尿素氮及光镜检查,另取2只作电镜检查。

摘要：目的评价中医辨证治疗对慢性肾脏病(CKD)3期患者的肾小球滤过率(eGFR)及蛋白尿的影响。方法采用多中心、双盲双模拟、随机对照试验设计方案,选择慢性肾小球肾炎的CKD 3期患者154例,分为中药组(中药颗粒剂+苯那普利模拟剂)、西药组(苯那普利+中药模拟剂)、中西组(中药颗粒剂+苯那普利),连续治疗24周。观察治疗后各组临床疗效,检测治疗前后不同时间患者eGFR、24小时尿蛋白定量的变化。结果中药组、西药组、中西组临床总有效率差异无统计学意义(P>0.05)。中药组从治疗后2周起,各时间点eGFR与治疗前比较差异均有统计学意义(P0.05)。中西组除治疗后2周、8周外,其余各时间点与治疗前比较差异均有统计学意义(P0.05)。治疗后24周,中西组24小时尿蛋白定量最少,优于中药组和西药组(P<0.05)。结论中医辨证治疗可明显改善CKD 3期患者的肾功能状况,中西药联用效果更好。

摘要：腹透管不通畅是影响腹透正常进行的常见原因。据文献报道和我们的观察，大网膜自腹透管侧孔钻入是引起腹透管不通畅的常见原因，表现为进或出液受阻，或进出均受阻（下称堵管）。为了防止大网膜钻入腹透管而引起堵管，我们设计了大网膜部分切除术，现将我们的观察结果报告如下。

摘要：Objective: To screen a triple helix-forming oligodeoxyribonucleotide (TFO) that can bind HBV core promoter at target site with high affinity and specificity, and to observe the ability of manganese porphyrin modified TFO to combine and cleave HBV ***: Similar homopurine domain (1 734-1 754) in HBV core promoter was selected as target *** corresponding TFOs were *** affinities and specificities of TFOs binding target sequence were tested with electrophoretic mobility shift and DNase Ⅰ footprinting *** selected best TFO was modified with manganese porphyrin and *** ability of the TFO derivative to cleave HBV DNA was observed with cleavage ***: Under the condition of 37℃ and pH 7.4, the TFO consisting of cytidylate and thymidylate (CT-TFO) and the parallel TFO consisting of guanylate and thymidylate (GT-TFOp) bound the target sequence weakly with Kd values much more than 10-6 mol/*** affinities of anti-parallel GT-TFO (GT-TFOap) and short TFO consisting of adenine nucleotide and guanylate (AG-TFOsh) binding the target sequence were higher than those of the formers, with Kd values of 5×10-7 mol/L and 2.5×10-8 mol/L *** AG-TFO (AG-TFOl) had the highest binding affinity with a Kd value of 3×10-9 mol/L among all the TFOs studied for sequence *** the presence of potassium monopersulfate, KHSO5, TFO modified with manganese porphyrin and acridine cleaved the target sequence where the triplex DNA ***: TFO containing AG or GT binds homopurine in HBV core promoter in adverse parallel direction to form triple ***-TFOl has the highest binding affinity among all the TFOs *** modified with manganese porphyrin, AG-TFOl completely binds and cleaves the target HBV DNA sequence where triplex DNA is formed.